5.265

0.29% 0.045

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $5.265, with a volume of 650.03K. It is up +0.29% in the last 24 hours and down -3.77% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Previous Close:

$5.22

Open:

$5.15

24h Volume:

650.03K

Relative Volume:

0.68

Market Cap:

$319.24M

Revenue:

$217.78M

Net Income/Loss:

$-239.55M

P/E Ratio:

-1.3003

EPS:

-4.0492

Net Cash Flow:

$-127.30M

1W Performance:

+4.28%

1M Performance:

-3.77%

6M Performance:

-15.56%

1Y Performance:

+20.07%

1-Day Range:

$5.13

$5.335

1-Week Range:

$4.849

$5.335

52-Week Range:

$4.27

$9.94

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

533

Twitter

Next Earnings Date

2026-07-30

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	5.28	315.62M	217.78M	-239.55M	-127.30M	-4.0492
VRTX Vertex Pharmaceuticals Inc	515.13	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.23	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.83	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.30	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.42	39.31B	5.76B	514.49M	1.10B	4.4813

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-05-26	Initiated	Truist	Buy
Nov-05-25	Initiated	B. Riley Securities	Buy
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

06:55 AM

Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat

06:55 AM

Aug 16, 2026

Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0

Aug 16, 2026

Aug 15, 2026

Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits

Aug 15, 2026

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits

Aug 15, 2026

Aug 14, 2026

Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits

Aug 14, 2026

Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us

Aug 14, 2026

Aug 13, 2026

AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan

Aug 13, 2026

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026

Aug 12, 2026

Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat

Aug 12, 2026

Aug 11, 2026

VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits

Aug 11, 2026

Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits

Aug 11, 2026

Aug 10, 2026

VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus

Aug 10, 2026

Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat

Aug 10, 2026

B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com

Aug 10, 2026

H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada

Aug 10, 2026

VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 10, 2026